The Hopkins Lupus Cohort is a unique 25 year, 2000 SLE patient longitudinal cohort in which patients are followed by protocol every 3 months, allowing study of time-varying (lupus activity, cardiovascular risk factors and, treatment) variables: 1) In the last RO-1 we successfully developed and published computed tomography angiography (CTA) for detection of non-calcified plaque in SLE and showed that it was associated with same day measures of SLE activity. In this RO-1, we will determine predictors of non-calcified plaque changes over time. We will bring an automated measure of non-calcified and calcified plaque burden to the clinic. 2) In the last RO-1 we successfully developed a consortium of U.S. sites interested in urine biomarkers of lupus nephritis activity, and discovered and published new biomarkers including urinary VCAM-1. In this RO-1 we have enlarged the consortium, arranged collaboration with the Glaxo Smith Kline belimumab lupus nephritis clinical trial to obtain longitudinal samples, and have begun our own urinary proteomics discovery program. We have already successfully brought urinary TWEAK to clinical trial stage, and anticipate bringing a panel of urinary biomarkers to the clinic for identification of lupus nephrits activity and prediction of treatment outcome. 3) In a past collaboration with Biogen Idec we found that BAFF and neutrophil gene signatures associate with same day SLE activity and predict activity over the next year. In this RO-1, we will continue that collaboration and determine whether these gene signatures are invariant in an individual or whether they change over time. If they change, we will evaluate the contributions of treatments and other variables. These investigations will demonstrate the utility of these signatures in indicating and predicting disease activity over time, so that they can be used in the clinic and in clinical trials.
The Hopkins Lupus Cohort is a longitudinal study of over 2,000 SLE patients followed every 3 months by protocol. This RO-1 explores three new outcomes: 1) predicting how a measure of coronary artery atherosclerosis, non-calcified plaque, changes over time;2) tracking renal activity through urine biomarkers and 3) determining how gene signatures contribute to disease activity and organ damage.
|Baer, Alan N; Petri, Michelle; Sohn, Jungsan et al. (2016) Antibodies to interferon-inducible protein-16 in primary SjÃ¶gren's syndrome are associated with markers of more severe diseas. Arthritis Care Res (Hoboken) :|
|Kiani, A N; Aukrust, P; Ueland, T et al. (2016) Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus. Lupus :|
|Wang, Yuchuan; Coughlin, Jennifer M; Ma, Shuangchao et al. (2016) Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [11C]DPA-713 positron emission tomography. Lupus :|
|Lloyd, Thomas E; Christopher-Stine, Lisa; Pinal-Fernandez, Iago et al. (2016) Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken) 68:66-71|
|Baer, Alan N; Petri, Michelle; Sohn, Jungsan et al. (2016) Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary SjÃ¶gren's Syndrome. Arthritis Care Res (Hoboken) 68:254-60|
|Hanly, John G; O'Keeffe, Aidan G; Su, Li et al. (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55:252-62|
|Domingues, Vinicius; Magder, Laurence S; Petri, Michelle (2016) Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med 3:e000107|
|Zollars, Eric; Courtney, Sean M; Wolf, Bethany J et al. (2016) Clinical Application of a Modular Genomics Technique in Systemic Lupus Erythematosus: Progress towards Precision Medicine. Int J Genomics 2016:7862962|
|Kim, Mimi Y; Buyon, Jill P; Guerra, Marta M et al. (2016) Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 214:108.e1-108.e14|
|Durcan, L; Petri, M (2016) Immunomodulators in SLE: Clinical evidence and immunologic actions. J Autoimmun 74:73-84|
Showing the most recent 10 out of 175 publications